Antibody Mediated Rejection in Pediatric Kidney Transplant Recipients: Practice Patterns, Report from the Paramour “Pediatric Renal AMR Outcomes” Study

N. Hayde¹, K. Twombley², I. Ashoor³, R. Engen⁴, L. Harshman⁵, R. Zahr⁶, C. Peterson⁷, S. McEwen⁸, A. Jain⁹, R. Garro¹⁰, M. Kallash¹¹, A. Mansuri¹², D. Puliyanda¹³

¹Montefiore Medical Center, Bronx, NY, ²Medical University of South Carolina, Charleston, SC, ³LCMCHealth, New Orleans, LA, ⁴Pediatrics, University of Wisconsin Madison, Madison, WI, ⁵University of Iowa Children's Hospital, Iowa City, IA, ⁶Le Bonheur Children's Hospital, Nashville, TN, ⁷University of Utah, Salt Lake City, UT, ⁸University of Minnesota, Minneapolis, MN, ⁹Wayne State, Troy, MI, ¹⁰Emory Universtiy, Atlanta, GA, ¹¹The Ohio State, Columbus, OH, ¹²Augusta University Medical Center, Augusta, GA, ¹³Cedars-Sinai Med Ctr, West Hollywood, CA

Meeting: 2022 American Transplant Congress

Abstract number: 836

Keywords: Antibodies, Immunosuppression, Multicenter studies, Pediatric

Topic: Clinical Science » Kidney » 43 - Kidney: Pediatrics

Session Information

Session Name: Kidney: Pediatrics

Session Type: Poster Abstract

Date: Saturday, June 4, 2022

Session Time: 5:30pm-7:00pm

Presentation Time: 5:30pm-7:00pm

Location: Hynes Halls C & D

*Purpose: There is insufficient data on children with AMR in the literature, and the optimal therapy for AMR is not well defined. We aim to describe the treatment patterns of pediatric nephrologist in treating AMR in the US.

*Methods: We collected data from 14 centers within the Pediatric Nephrology Research Consortium. Pediatric renal transplant recipients between the ages of 0 to 18 years old at time of transplant who had biopsy proven AMR between 12/31/2009-12/31/2019 and followed for at least 12 consecutive months were included. P values for race and gender were obtained by comparing to SRTR data.

*Results: We have treatment data on 127 AMR episodes (Table1).

*Conclusions: Caucasian adolescent males were the most common group to have AMR in our cohort. Most of our patients were on steroid, CNI, and MMF therapy at the time of AMR. Most common treatment was IVIG, followed by Rituximab, and pheresis. Prospective studies are needed to determine outcomes based on treatment patterns.

To cite this abstract in AMA style:

Hayde N, Twombley K, Ashoor I, Engen R, Harshman L, Zahr R, Peterson C, McEwen S, Jain A, Garro R, Kallash M, Mansuri A, Puliyanda D. Antibody Mediated Rejection in Pediatric Kidney Transplant Recipients: Practice Patterns, Report from the Paramour “Pediatric Renal AMR Outcomes” Study [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/antibody-mediated-rejection-in-pediatric-kidney-transplant-recipients-practice-patterns-report-from-the-paramour-pediatric-renal-amr-outcomes-study/. Accessed May 21, 2025.

« Back to 2022 American Transplant Congress